Hormone receptor profiling is necessary for breast cancer treatment. Just as no two people are exactly alike, no two breast cancers are exactly the same, either. The pathology report contains certain pertinent information including:
- Non-invasive or Invasive breast cancer
- Histologic type and Cell grade
- Size
- Surgical margins
- Lymphatic or vascular system invasion
- Lymph node involvement
- Hormone receptor status
- HER2 status
At TSL, we use a synoptic reporting template which ensures that all our reports are standardised and can be used worldwide.
The breast biopsy/mastectomy report is available for download/pick-up/delivery within five working days. This is followed by ER, PR and HER2 analysis on request.
We provide in-house automated immunohistochemistry for hormone receptor (ER, PR) analysis and HER2 testing as well as partnerships with overseas laboratories to provide FISH testing for indeterminate HER2 cancers. Hormone receptor analysis reports are available within 2 weeks. We also offer Oncotype DX testing to help you make a more informed decision on treatment for ER positive breast cancers.
